文献速递类风湿关节炎脊柱关节炎其他结缔组织病

超声引导穿刺、超声引导门钳与关节镜滑膜活检的患者报告结局与安全性比较:欧洲五中心研究

Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe.
PubMed 文献 · RMD Open · 2018-10-26

该欧洲五中心研究记录了524例滑膜活检操作,比较超声引导针吸活检(US-NB)、超声引导门钳活检(US-P&F)与关节镜引导活检(AGSB)的安全性及患者报告结局。结果显示不良事件发生率1.5%,三种方法间无差异;活检后2周所有患者报告结局均改善,且方法间无差异。活检过程中使用皮质类固醇或序贯活检未增加不良事件。

要点

  • 三种滑膜活检方法不良事件发生率低且无显著差异。
  • 活检后2周关节疼痛、僵硬和肿胀均改善,方法间无差异。
  • 活检时使用皮质类固醇或序贯活检安全且耐受良好。

核心结论

  • US-NB、US-P&F与AGSB三种滑膜活检方法在安全性和患者耐受性方面无显著差异。
  • 活检过程中使用皮质类固醇及序贯活检均安全且耐受良好。

研究设计与样本

  • 欧洲五中心研究,收集活检当天及术后7-14天的数据。
  • 共记录524例滑膜活检操作:US-NB 402例、US-P&F 65例、AGSB 57例。
  • 采用线性回归比较组间差异,调整疾病活动度、皮质类固醇治疗和活检前患者报告结局值,并考虑重复测量。

主要发现

  • 共发生8例不良事件(1.5%),三种活检方法间无差异(p=0.55)。
  • 活检后2周所有患者报告结局均改善,且方法间活检后变化无差异。
  • 肌肉注射(n=62)或关节腔内注射(n=38)皮质类固醇未导致更多不良事件(p=0.81),并与活检后肿胀减轻相关(p<0.01)。
  • 序贯活检(n=103例患者)未导致更多不良事件(p=0.61)或患者报告结局恶化。

关键数值与推荐

  • 关节疼痛、肿胀和僵硬指数采用0-100 mm视觉模拟量表(VAS)记录。
  • 定性结局变量采用五点李克特量表。
  • 不良事件发生率1.5%(8例/524例操作)。

临床怎么用

  • 临床选择滑膜活检方法时可考虑US-NB、US-P&F或AGSB,三者安全性和患者耐受性相似。
  • 活检过程中可安全使用皮质类固醇,且可能有助于减轻术后肿胀。
  • 序贯活检在需要时可行,不增加不良事件或恶化患者报告结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We present a European multicenter study, comparing safety data and patient-reported outcomes (PRO) from patients undergoing synovial biopsy using ultrasound-guided needle biopsy (US-NB), ultrasound-guided portal and forceps (US-P&F) or arthroscopic-guided (AG) procedures. OBJECTIVES: To describe safety and PRO data on joint indices of pain, stiffness and swelling before and after biopsy, procedural discomfort, joint status compared with before biopsy and willingness to undergo a second biopsy for each technique and compare the three techniques. To evaluate the impact on PRO and safety data of corticosteroid therapy as part of the biopsy procedure and sequential biopsy procedures. METHODS: Data were collected on the day of biopsy and 7-14 days postprocedure. Joint pain, swelling and stiffness indices were recorded as 0-100 mm Visual Analogue Scale; qualitative outcome variables on five-point Likert scales. Groups were compared with linear regression, adjusting for disease activity, corticosteroid therapy and prebiopsy PRO value and accounting for repeated measurements. RESULTS: A total of 524 synovial biopsy procedures were documented (402 US-NB, 65 US-P&F and 57 AGSB). There were eight adverse events (1.5%) with no difference between biopsy methods (p=0.55). All PROs were improved 2 weeks postprocedure, and there were no differences in postbiopsy change in PROs between biopsy methods. Corticosteroid administration, whether intramuscular (n=62) or intra-articular (n=38), did not result in more adverse events (p=0.81) and was associated with reduction in postbiopsy swelling (p<0.01). Sequential biopsy procedures (n=103 patients) did not result in more adverse events (p=0.61) or worsening in PRO data. CONCLUSION: Overall, our results do not suggest a significant difference in safety or patient tolerability between US-NB, US-P&F and AGSB sampling. Further, corticosteroid therapy as part of the biopsy procedure and sequential biopsies is safe and well tolerated in patients.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Just SA, Humby F, Lindegaard H, et al. Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. RMD Open. 2018. PMID: 30488001. doi:10.1136/rmdopen-2018-000799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。